Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia

• Prif Awduron: Rubin Cheng (Awdur), Yilan Huang (Awdur), Yun Fang (Awdur), Qirui Wang (Awdur), Meixiu Yan (Awdur), Yuqing Ge (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Context A portion of patients with chronic myeloid leukaemia (CML) develop resistance to the Bcr-Abl tyrosine kinase inhibitors (TKIs), limiting the clinical applications. Previous results have demonstrated the synergistic effects between cryptotanshinone (CPT) and imatinib on apoptosis of CML cells...